ES2258716T3 - Compuestos de 3,4-dihidroquinolin-2(1h)-ona como antagonistas del receptor nr2b. - Google Patents

Compuestos de 3,4-dihidroquinolin-2(1h)-ona como antagonistas del receptor nr2b.

Info

Publication number
ES2258716T3
ES2258716T3 ES03715209T ES03715209T ES2258716T3 ES 2258716 T3 ES2258716 T3 ES 2258716T3 ES 03715209 T ES03715209 T ES 03715209T ES 03715209 T ES03715209 T ES 03715209T ES 2258716 T3 ES2258716 T3 ES 2258716T3
Authority
ES
Spain
Prior art keywords
pain
compound
pharmaceutically acceptable
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03715209T
Other languages
English (en)
Spanish (es)
Inventor
M. Pfizer Global Research and Development KAWAMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2258716T3 publication Critical patent/ES2258716T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES03715209T 2002-04-26 2003-04-15 Compuestos de 3,4-dihidroquinolin-2(1h)-ona como antagonistas del receptor nr2b. Expired - Lifetime ES2258716T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26
US375939P 2002-04-26

Publications (1)

Publication Number Publication Date
ES2258716T3 true ES2258716T3 (es) 2006-09-01

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03715209T Expired - Lifetime ES2258716T3 (es) 2002-04-26 2003-04-15 Compuestos de 3,4-dihidroquinolin-2(1h)-ona como antagonistas del receptor nr2b.

Country Status (15)

Country Link
US (1) US6713490B2 (https=)
EP (1) EP1499606B8 (https=)
JP (1) JP2005524696A (https=)
AR (1) AR039663A1 (https=)
AT (1) ATE325117T1 (https=)
AU (1) AU2003219398A1 (https=)
BR (1) BR0309778A (https=)
CA (1) CA2483636A1 (https=)
DE (1) DE60305026T2 (https=)
ES (1) ES2258716T3 (https=)
MX (1) MXPA04010549A (https=)
PA (1) PA8572601A1 (https=)
TW (1) TW200406402A (https=)
UY (1) UY27776A1 (https=)
WO (1) WO2003091241A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO2005035523A1 (en) * 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
EP1736474A4 (en) * 2004-04-07 2010-04-21 Kyowa Hakko Kirin Co Ltd piperidine
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010036937A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
WO2010113109A1 (en) * 2009-03-31 2010-10-07 Link Research & Grants Corporation Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1991017156A1 (en) 1990-05-10 1991-11-14 Pfizer Inc Neuroprotective indolone and related derivatives
DK0666854T3 (da) 1992-10-30 1997-04-28 Pfizer Neurobeskyttende 3,4-dihydro-2(1H)-quinolon forbindelser
PE20020291A1 (es) 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda

Also Published As

Publication number Publication date
WO2003091241A1 (en) 2003-11-06
US6713490B2 (en) 2004-03-30
JP2005524696A (ja) 2005-08-18
PA8572601A1 (es) 2004-12-16
EP1499606A1 (en) 2005-01-26
TW200406402A (en) 2004-05-01
CA2483636A1 (en) 2003-11-06
ATE325117T1 (de) 2006-06-15
DE60305026T2 (de) 2006-10-12
BR0309778A (pt) 2005-03-08
EP1499606B8 (en) 2006-08-30
DE60305026D1 (de) 2006-06-08
UY27776A1 (es) 2003-11-28
AR039663A1 (es) 2005-03-02
AU2003219398A1 (en) 2003-11-10
US20030216430A1 (en) 2003-11-20
MXPA04010549A (es) 2005-02-17
EP1499606B1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
ES2258716T3 (es) Compuestos de 3,4-dihidroquinolin-2(1h)-ona como antagonistas del receptor nr2b.
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
CN101583601B (zh) 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
TWI465452B (zh) 螺－吲哚酮化合物之鏡像異構物及其作為治療劑之用途
JP5420534B2 (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
ES2537803T3 (es) Compuesto de tetrahidroisoquinolina 1-sustituida
CN109071426A (zh) 取代的苯甲酰胺及其使用方法
TW201217386A (en) Heterocyclic compound and use thereof
KR20200133358A (ko) 옥사디아졸 일시적 수용체 전위 채널 억제제
JP2024023383A (ja) 社会的機能障害の治療方法
CN101801953A (zh) 作为trpv1拮抗剂的四氢吡啶甲酰胺衍生物
CN108601775A (zh) 阿片受体配体和细胞色素p450抑制剂的组合
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
CN109476628A (zh) 作为trpa1调节剂的磺酰基环烷基酰胺化合物
KR20010024076A (ko) 5-ＨＴ 재흡수 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는 부분작용제의 배합물
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
CN101090898A (zh) 5－ht7受体拮抗剂
JP7041141B2 (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
TW201630902A (zh) 化合物、組合物及方法
CN106986859B (zh) 吲哚衍生物及其用途
TW202513551A (zh) Trek(twik相關的k+通道)通道功能的抑制劑
TW202216674A (zh) 用於心理疾病或心理強化的有益苯并呋喃組合物
CN118284607A (zh) 用于治疗疾病和障碍的lsd衍生物、合成和方法
HK1209736A1 (en) N-substituted benzamides and methods of use thereof